tiprankstipranks
Trending News
More News >
Allergy Therapeutics (GB:AGY)
:AGY
Advertisement

Allergy Therapeutics (AGY) AI Stock Analysis

Compare
16 Followers

Top Page

GB:AGY

Allergy Therapeutics

(LSE:AGY)

Rating:53Neutral
Price Target:
8.00p
▲(0.00%Upside)
Allergy Therapeutics has significant financial challenges, which are the most impactful factor on its stock score. However, technical analysis shows some positive momentum, and promising corporate events suggest potential future growth, partially offsetting financial weaknesses. Valuation concerns remain due to negative earnings.

Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)

Allergy Therapeutics Business Overview & Revenue Model

Company DescriptionAllergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
How the Company Makes MoneyAllergy Therapeutics generates revenue primarily through the sale of its allergy immunotherapy products. The company's key revenue streams include direct sales of its proprietary allergy vaccines to healthcare providers, clinics, and hospitals. Additionally, the company may engage in partnerships and licensing agreements with other pharmaceutical companies to expand the reach and distribution of its products. Significant factors contributing to its earnings include ongoing research and development activities aimed at enhancing product efficacy and the expansion of its product portfolio to address a broader range of allergic conditions.

Allergy Therapeutics Financial Statement Overview

Summary
Allergy Therapeutics is facing significant financial difficulties, with declining revenues, negative net profit margins, and high leverage indicated by the balance sheet. The negative operating and free cash flows further highlight the company's financial strain and liquidity issues.
Income Statement
42
Neutral
The company has faced declining revenue over the past two years, with a noticeable revenue decrease in the most recent year. Gross profit margin decreased from previous years, and the net profit margin is negative, indicating losses. EBIT and EBITDA margins are also negative, suggesting operational challenges and reduced profitability.
Balance Sheet
30
Negative
The balance sheet shows a high debt-to-equity ratio, indicating significant leverage. Stockholders' equity has drastically decreased, impacting the equity ratio negatively. The return on equity is negative due to consistent net losses, highlighting financial instability.
Cash Flow
38
Negative
Operating cash flow is negative and declining, highlighting cash management issues. The free cash flow remains negative, and the free cash flow to net income ratio is unfavorable. Despite a positive financing cash flow, overall cash flow indicators reflect financial strain.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue55.20M59.59M72.77M84.33M78.20M
Gross Profit29.74M32.69M48.95M61.80M57.51M
EBITDA-30.74M-36.24M-8.69M7.61M11.69M
Net Income-40.22M-43.07M-13.78M2.89M7.06M
Balance Sheet
Total Assets64.83M66.77M72.95M88.09M86.22M
Cash, Cash Equivalents and Short-Term Investments12.91M14.85M20.52M40.27M36.96M
Total Debt30.99M35.99M10.53M11.17M12.18M
Total Liabilities61.12M64.70M35.18M39.55M42.44M
Stockholders Equity3.71M2.07M37.77M48.53M43.78M
Cash Flow
Free Cash Flow-35.54M-35.59M-17.17M5.95M9.73M
Operating Cash Flow-32.14M-30.92M-14.11M8.52M12.28M
Investing Cash Flow-1.20M-4.67M-3.06M-2.76M-2.77M
Financing Cash Flow31.43M29.91M-2.64M-2.03M-110.00K

Allergy Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.00
Price Trends
50DMA
7.46
Positive
100DMA
6.98
Positive
200DMA
6.51
Positive
Market Momentum
MACD
0.20
Positive
RSI
54.33
Neutral
STOCH
54.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Positive. The current price of 8 is above the 20-day moving average (MA) of 7.98, above the 50-day MA of 7.46, and above the 200-day MA of 6.51, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AGY.

Allergy Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
£4.38B15.6415.79%0.15%5.83%83.35%
53
Neutral
£381.32M-369.20%4.50%74.32%
50
Neutral
AU$2.61B3.12-57.47%2.45%36.73%13.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:AGY
Allergy Therapeutics
8.00
2.98
59.36%
GB:HIK
Hikma Pharmaceuticals
1,995.00
187.93
10.40%

Allergy Therapeutics Corporate Events

Business Operations and StrategyFinancial Disclosures
Allergy Therapeutics Maintains Stable Performance Amid Strategic Growth Initiatives
Neutral
Jul 21, 2025

Allergy Therapeutics reported stable financial performance for the year ending June 2025, with revenues slightly declining to £55.0 million from £55.2 million in 2024. The company is strategically positioned for growth, leveraging its registered product portfolio amid changing German regulations and advancing key R&D programs, including the Grass MATA MPL and VLP Peanut trials. Despite the need for additional funding from August, major shareholders remain supportive, ensuring continued progress in both commercial and innovative pipeline areas.

Private Placements and FinancingBusiness Operations and Strategy
Allergy Therapeutics Issues Over 250 Million Warrants Amid Financial Strategy
Neutral
Jul 11, 2025

Allergy Therapeutics has issued 250,674,403 warrants to subscribe for new ordinary shares as part of its financial arrangements with SkyGem Acquisition Limited and Southern Fox Investments Limited. This issuance is linked to a £50 million loan facility, under which the company drew £10 million, necessitating the issuance of warrants. Additionally, 674,403 warrants were issued to Hayfin Healthcare Opportunities LuxCo S.a.r.l. due to anti-dilution rights. This move is part of the company’s strategy to manage its financial obligations and could impact its market positioning by potentially increasing its share capital.

Product-Related AnnouncementsBusiness Operations and Strategy
Allergy Therapeutics Unveils Promising Research at EAACI 2025
Positive
Jun 13, 2025

Allergy Therapeutics announced key scientific findings at the EAACI 2025 Congress, highlighting advancements in their research portfolio. The company presented promising results from its peanut allergy vaccine candidate and Grass MATA MPL immunotherapy, both showing potential to transform patient care by improving quality of life and inducing beneficial immune responses. These developments underscore the company’s commitment to expanding its VLP platform in food allergies and enhancing treatment options for allergic diseases.

Other
Allergy Therapeutics and EAACI Honor Early Career Researcher
Positive
Jun 10, 2025

Allergy Therapeutics, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), announced Dr. Janice Layhadi as the winner of the EAACI Early Career Research Award. This award supports young researchers in allergen immunotherapy, providing essential funding to advance their research. Dr. Layhadi’s work focuses on biomarker discovery in allergen immunotherapy, which is expected to enhance understanding and treatment of allergic conditions, ultimately improving patient outcomes.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 01, 2025